Developer docs
API playgroundTry for free, no card

Search company profiles

SK biotek

Full company profile

uuid000egdl

Namestring
SK biotek
Legal namestring
SK pharmteco Inc.
Websiteurl
skbiotek.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

SK biotek operates as a contract development and manufacturing organization (CDMO) specializing in small molecule active pharmaceutical ingredient (API) production, operating as a subsidiary brand within the SK pharmteco platform. The company provides end-to-end services spanning API drug substance development, custom API manufacturing, analytical services, and regulatory support, serving global pharmaceutical companies (primary segment) and biotechnology companies (secondary segment) from clinical through commercial scale. Its manufacturing footprint exceeds 1,000 m3 of capacity distributed across three continents, enabling gram-to-multi-ton production with full cGMP compliance.

The company's technical differentiation rests on proprietary process technologies including continuous flow processing, simulated moving bed (SMB) chromatography, biocatalysis, particle engineering, custom catalyst design, and specialized handling of high-potency APIs (HPAPIs) including cytotoxic compounds and antibody-drug conjugate (ADC) payloads and linkers. Beyond small molecules, the platform extends into peptide synthesis and viral vector manufacturing (AAV, Adenovirus, Lentivirus) for gene therapy applications. A dedicated project management model assigns a single point of contact per program to manage scope, timelines, and deliverables.

SK biotek generates revenue through project-based B2B contracts with pharmaceutical and biotech clients, with pricing negotiated per project based on scale, complexity, and service requirements. The go-to-market is direct enterprise sales with no channel intermediaries, supported by technical content marketing, conference participation at major industry events (CPHI, TIDES, BOS, World ADC), and thought leadership through white papers and webinars. The entity is privately held within the SK Group ecosystem, with legal operations in the United States (SK pharmteco Inc.), South Korea (SK Biotek Korea), and Ireland (SK Biotek Ireland).

Short descriptiontext

SK biotek is a CDMO providing small molecule API development and manufacturing services, plus peptide and viral vector capabilities, to global pharmaceutical and biotech companies across clinical to commercial stages, operating within the SK pharmteco platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRancho Cordova, United States
HQ citystring
Rancho Cordova
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract API manufacturing, small molecule CDMO, pharmaceutical development services, drug substance manufacturing, cGMP API production
Industry4 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical API Contract Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

CDMO services providing drug substance development and manufacturing for pharmaceutical and biotech companies across clinical to commercial phases. Revenue generated through project-based contracts with pharmaceutical clients for API manufacturing, process development, and regulatory support services.

skpharmteco.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SK biotek is a Contract Development and Manufacturing Organization (CDMO) that produces Active Pharmaceutical Ingredients (APIs) for pharmaceutical and biotech companies. Its core business centers on small molecule manufacturing, with additional capabilities in peptides and viral vectors, delivered under cGMP standards to support global drug development and commercial supply.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SK biotek operates as part of SK pharmteco, a Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical manufacturing services. The portfolio includes Small Molecule CDMO Services (API drug substance development, custom API manufacturing, analytical services, and regulatory support), Small Molecule Specialties (high potency APIs, chromatography, continuous flow processing, biocatalysis, and particle engineering), Peptide Synthesis, and Viral Vectors services (including AAV, Adenovirus, and Lentivirus manufacturing for gene therapies). The company offers end-to-end capabilities from clinical to commercial scale manufacturing with cGMP compliance.

Product and service1 record
1Small Molecule API Manufacturing
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SK biotek

Pharmaceutical API Contract Manufacturingskbiotek.com

SK biotek is a CDMO providing small molecule API development and manufacturing services, plus peptide and viral vector capabilities, to global pharmaceutical and biotech companies across clinical to commercial stages, operating within the SK pharmteco platform.

What SK biotek does

SK biotek operates as a contract development and manufacturing organization (CDMO) specializing in small molecule active pharmaceutical ingredient (API) production, operating as a subsidiary brand within the SK pharmteco platform. The company provides end-to-end services spanning API drug substance development, custom API manufacturing, analytical services, and regulatory support, serving global pharmaceutical companies (primary segment) and biotechnology companies (secondary segment) from clinical through commercial scale. Its manufacturing footprint exceeds 1,000 m3 of capacity distributed across three continents, enabling gram-to-multi-ton production with full cGMP compliance.

The company's technical differentiation rests on proprietary process technologies including continuous flow processing, simulated moving bed (SMB) chromatography, biocatalysis, particle engineering, custom catalyst design, and specialized handling of high-potency APIs (HPAPIs) including cytotoxic compounds and antibody-drug conjugate (ADC) payloads and linkers. Beyond small molecules, the platform extends into peptide synthesis and viral vector manufacturing (AAV, Adenovirus, Lentivirus) for gene therapy applications. A dedicated project management model assigns a single point of contact per program to manage scope, timelines, and deliverables.

SK biotek generates revenue through project-based B2B contracts with pharmaceutical and biotech clients, with pricing negotiated per project based on scale, complexity, and service requirements. The go-to-market is direct enterprise sales with no channel intermediaries, supported by technical content marketing, conference participation at major industry events (CPHI, TIDES, BOS, World ADC), and thought leadership through white papers and webinars. The entity is privately held within the SK Group ecosystem, with legal operations in the United States (SK pharmteco Inc.), South Korea (SK Biotek Korea), and Ireland (SK Biotek Ireland).

SK biotek firmographics

Firmographics
Name
SK biotek
Legal name
SK pharmteco Inc.
Website
https://skbiotek.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
SK biotek is a CDMO providing small molecule API development and manufacturing services, plus peptide and viral vector capabilities, to global pharmaceutical and biotech companies across clinical to commercial stages, operating within the SK pharmteco platform.
Ownership category
akta.pro rank

SK biotek industry classification

Industry
Product category
Pharmaceutical API Contract Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract API manufacturing
  • Small molecule CDMO
  • Pharmaceutical development services
  • Drug substance manufacturing
  • CGMP API production

Where SK biotek is headquartered

Location

Headquarters

HQ city
Rancho Cordova
HQ country
United States
HQ region
North America

Offices2 records

Markets served

SK biotek business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

  1. Contract Development and Manufacturing Services: CDMO services providing drug substance development and manufacturing for pharmaceutical and biotech companies across clinical to commercial phases. Revenue generated through project-based contracts with pharmaceutical clients for API manufacturing, process development, and regulatory support services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

SK biotek product offering

Product offering

Core offering

SK biotek is a Contract Development and Manufacturing Organization (CDMO) that produces Active Pharmaceutical Ingredients (APIs) for pharmaceutical and biotech companies. Its core business centers on small molecule manufacturing, with additional capabilities in peptides and viral vectors, delivered under cGMP standards to support global drug development and commercial supply.

Product overview

SK biotek operates as part of SK pharmteco, a Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical manufacturing services. The portfolio includes Small Molecule CDMO Services (API drug substance development, custom API manufacturing, analytical services, and regulatory support), Small Molecule Specialties (high potency APIs, chromatography, continuous flow processing, biocatalysis, and particle engineering), Peptide Synthesis, and Viral Vectors services (including AAV, Adenovirus, and Lentivirus manufacturing for gene therapies). The company offers end-to-end capabilities from clinical to commercial scale manufacturing with cGMP compliance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Small Molecule API Manufacturing

Companies that use SK biotek

Customer profile

Segments2 records

Ideal customer profiles2 records

SK biotek technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

SK biotek partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

SK biotek competitors and assessment

Company assessment

Market position

Strengths1 record

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

SK biotek social profiles

Digital presence

SK biotek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SK biotek leadership team

Management profile

Number of profiles

Profiles3 records

SK biotek subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SK biotek funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SK biotek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SK biotek

What does SK biotek do?

SK biotek is a Contract Development and Manufacturing Organization (CDMO) that produces Active Pharmaceutical Ingredients (APIs) for pharmaceutical and biotech companies. Its core business centers on small molecule manufacturing, with additional capabilities in peptides and viral vectors, delivered under cGMP standards to support global drug development and commercial supply.

Is SK biotek a public or private company?

SK biotek is a private company. It is classified as corporate owned and is currently operating.

When was SK biotek founded?

SK biotek was founded in 2018. It employs 101 to 250 people.

Where is SK biotek based?

SK biotek is headquartered in Rancho Cordova, United States, in the North America region.

How does SK biotek make money?

One revenue line is on record: contract Development and Manufacturing Services.

Does SK biotek have an API?

No public API is recorded for SK biotek.

What industry is SK biotek in?

SK biotek's product category is Pharmaceutical API Contract Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Irish TimesSick pay award of €500 by WRC to pharma employee overturned on appealPharmaceutical firm SK Biotek successfully appealed a Workplace Relations Commission decision at the Labour Court that had awarded €500 in compensation to former employee Shannon Reina for being excluded from the company's sick pay scheme. The court ruled that section 9(1) of the relevant Act absolutely exempts the company from applying the statutory sick leave scheme to employees who do not meet eligibility criteria under its superior company scheme. This decision reverses the lower tribunal's ruling and establishes that employers with generally more favorable sick leave policies are not obligated to provide statutory benefits when employees are excluded due to not meeting the scheme's own conditions.PR NewswireAMPAC Fine Chemicals et SK biotek deviennent une nouvelle société américaine axée sur le support étendu au secteur pharmaceutique mondialSK Holdings, the Korean portfolio company of SK Group, has created SK pharmteco, a US-based contract manufacturing organization that consolidates AMPAC Fine Chemicals and SK biotek operations from Korea, Ireland, and the United States. The new entity, headquartered in Sacramento, California, is led by former AFC CEO Aslam Malik and possesses over 1,000 cubic meters of pharmaceutical manufacturing capacity across six production facilities. The constituent companies will continue operating under their established brand identities while providing comprehensive support to existing client product registrations worldwide, with plans for further growth in the coming years.PR NewswireAMPAC Fine Chemicals y SK biotek se convierten en la corporación estadounidense para el sector farmacéutico mundialSK Holdings, the holding company of South Korea's SK Group, founded SK pharmteco, a US-based contract pharmaceutical manufacturing organization (CMO) that consolidates AMPAC Fine Chemicals and SK biotek operations across three countries. The newly formed company is led by Aslam Malik, former CEO of AMPAC Fine Chemicals, and is headquartered in Sacramento, California, with production facilities in the United States, Ireland, and South Korea. SK pharmteco claims over 1,000 cubic meters of CMO production capacity and positions itself to serve global pharmaceutical and biotechnology clients at an expanded scale.PR NewswireAus AMPAC Fine Chemicals und SK biotek wird neues US-Unternehmen, das die weltweite Pharmaindustrie besser unterstützen willSK Holdings, parent company of South Korea's SK Group, established SK pharmteco on September 17, 2019, creating a consolidated US-based contract manufacturing organization (CMO) for the global pharmaceutical industry by merging AMPAC Fine Chemicals (USA) with SK biotek operations in Korea and Ireland. The new company, headquartered in Sacramento, California, with CEO Aslam Malik (formerly of AFC), commands over 1,000 m³ of CMO production capacity across six manufacturing facilities. The constituent companies will continue operating under their existing identities while leveraging the consolidated entity's expanded global footprint and service capabilities.PR NewswireAMPAC Fine Chemicals and SK biotek Become New US Corporation Focused on Expanded Support to the World's Pharmaceutical IndustrySK Holdings formed SK pharmteco, a U.S.-based contract manufacturing organization, by combining AMPAC Fine Chemicals and SK biotek's operations. The consolidated CMO has over 1000 m3 production capacity and plans further growth. It will continue operating with existing customer product registrations.PR NewswireAMPAC Fine Chemicals and SK biotek Become New US Corporation Focused on Expanded Support to the World's Pharmaceutical IndustrySK Holdings formed SK pharmteco, a U.S.-based contract manufacturing organization, by combining AMPAC Fine Chemicals and SK biotek's operations. The consolidated CMO, led by Aslam Malik, has over 1000 m3 production capacity and plans further growth. Existing company identities will continue operating for customer product registrations.FiercePharmaSouth Korean CDMO consolidates, plants flag in CaliforniaSK Holdings merged its SK biotek units in Korea and Ireland with Ampac Fine Chemicals in the U.S. to form SK Pharmteco, headquartered in Sacramento, California. The company named Ampac's CEO Aslam Malik to lead the CDMO, aiming to attract customers and sharpen its competitive edge.Silicon RepublicSouth Korean firm SK Biotek invests in Irish pharma campusSK Biotek acquired the former Bristol-Myers Squibb API facility in Swords, Co Dublin, with over 360 staff transitioning from 1 January. The company will operate the site as a standalone CDMO, adding marketing, R&D, and API capacity. The acquisition supports SK Biotek's strategy to become a top-level global contract pharmaceuticals firm.The Korea HeraldSK Biotek acquires BMS facility in IrelandSK Biotek, a subsidiary of SK Holdings, will acquire a Bristol-Myers Squibb manufacturing facility in Swords, Ireland, for small molecule active pharmaceutical ingredients. The 81,000-liter plant, which produces ingredients for Eliquis, will operate as a stand-alone contract development manufacturing organization. The deal is expected to be completed in the fourth quarter of 2017.